Article

Anticipation is key to managing intraoperative floppy iris syndrome

San Francisco-Questioning patients before cataract surgery about whether they are taking alpha-1 blockers, such as tamsulosin (Flomax, Boehringer Ingelheim), has become increasingly important in light of the observation by David F. Chang, MD, and John R. Campbell, MD, that the drug, which is used to treat the symptoms of benign prostatic hyperplasia, can cause intraoperative floppy iris syndrome (IFIS).

Dr. Chang reported at the recent American Society of Cataract and Refractive Surgery annual meeting that the complication rate is acceptably low when surgeons are forewarned about use of the alpha-blocker. Dr. Chang is clinical professor of ophthalmology, University of California, San Francisco, and is in private practice in Los Altos, CA. Dr. Campbell is in private practice in San Rafael, CA.

Other surgeons conducting retrospective chart reviews found high complication rates with IFIS. Colleague Richard Beller, MD, Napa, CA, found that in five of his six total cases of posterior capsular rupture since 2000, the patients had been taking tamsulosin. Likewise, Bonnie Henderson, MD, affiliated with the Massachusetts Eye and Ear Institute, Boston, retrospectively reviewed all the cases in the resident database with a history of tamsulosin use. The review covered the 2 years immediately prior to the IFIS report, and five of the seven cases identified had had posterior capsule rupture.

"This raised the questions of what to tell our patients taking tamsulosin, what to tell colleagues in urology about prescribing the drug, and what would the complication rate be if surgeons knew in advance to anticipate the IFIS," Dr. Chang explained.

Prospective trial

In light of these questions, Dr. Chang organized a prospective 10-site U.S. trial that started in 2005. A total of 167 consecutive patients undergoing cataract surgery and taking tamsulosin were enrolled over a 6-month period. Participating surgeons were asked to use one of four management strategies: 2.3% sodium hyaluronate (Healon5, Advanced Medical Optics [AMO]), iris hooks, pupil expansion rings, or atropine drops administered preoperatively.

"We were not performing a randomized trial to determine which technique was superior. We wanted to allow surgeons to do whatever they believed was appropriate-including the combination of multiple strategies in the same case if needed," Dr. Chang explained.

"Most of the procedures," Dr. Chang reported, "were performed using either sodium hyaluronate or iris hooks. About two-thirds of the cases had mild to moderate nuclear density, and one-third of the nuclei were dense. Most surgeries were performed using topical anesthesia and a phaco chop technique."

In addition, the surgeons performing the surgeries were highly experienced.

Related Videos
AAO 2024: Matt Giegengack, MD: Injectable endothelial cell therapy shows promise for improving vision and reducing glare in corneal edema
EyeCon 2024: Adam Wenick, MD, talks about myopic interventions across the lifespan
Adam Wenick, MD, chairs EyeCon session: New treatments in geographic atrophy from detection to intervention
EyeCon 2024: Laura M. Periman, MD, shares her passion for dry eye disease, discussing her surprising discovery of the Alpenglow Sign in Demodex blepharitis
David Eichenbaum, MD, presents advances in AMD therapy, highlights different mechanisms with a common goal
Cochair Kelly K. Nichols, OD, PhD, MPH, FAAO, highlights her passion for dry eye research and the vital collaboration between ophthalmology and optometry
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
© 2024 MJH Life Sciences

All rights reserved.